GT Biopharma submits IND for GTB-5550 TriKE targeting B7-H3 expressing solid tumors with NK cell activation
Find out how GT Biopharma’s IND filing for its B7-H3-targeted TriKE GTB-5550 could advance NK cell immunotherapy for solid tumors.
Lilly and NVIDIA commit $1bn to AI co-innovation lab for next-gen drug discovery
Eli Lilly and Company and NVIDIA have announced the formation of a co-innovation lab aimed at accelerating drug discovery using AI, robotics, and advanced compute. With a planned $1 billion investment over five years, the lab will leverage NVIDIA’s BioNeMo platform and Vera Rubin architecture alongside Lilly’s drug development expertise. The initiative represents one of […]
HMNC Brain Health reports Phase 2b efficacy signals for BH-200 in genetically defined depression patients at ACNP
Find out how HMNC Brain Health’s Phase 2b BH-200 data at ACNP reveal genetic responder signals that could advance precision psychiatry in depression treatment.
Ocugen’s OCU410 shows early Phase 2 promise as a modifier gene therapy for geographic atrophy in dry AMD
Find out how Ocugen’s early Phase 2 results for OCU410 are shaping a new gene therapy approach for geographic atrophy in dry AMD.
Clinical data show Vaxart oral norovirus vaccine induces maternal and infant immunity
Find out how Vaxart’s oral bivalent norovirus vaccine induced immune responses in lactating women and enabled antibody transfer to breastfed infants.
LUCE-1 Phase 1/2 study fully enrolled as AAVantgarde evaluates AAVB-081 gene therapy in Usher syndrome type B retinitis pigmentosa
Find out how AAVantgarde Bio’s fully enrolled LUCE-1 Phase 1/2 trial advances AAVB-081 gene therapy development for Usher syndrome-related retinitis pigmentosa.
What does Swissmedic approval of Santhera’s AGAMREE mean for long-term steroid treatment in Duchenne muscular dystrophy?
Swissmedic approves Santhera’s AGAMREE for Duchenne muscular dystrophy. Find out how vamorolone could reshape long-term steroid treatment strategies.
Johnson & Johnson’s TECVAYLI may redefine second-line myeloma care after MajesTEC-9
TECVAYLI outperformed standard regimens in relapsed/refractory myeloma. Find out what the Phase 3 MajesTEC-9 trial means for future treatment lines.
Can UT Health San Antonio’s GRK2 inhibitor reduce opioid use in burn trauma care?
Can UT Health San Antonio’s GRK2-targeted therapy reduce opioid use and scarring in burn trauma? Find out what’s next for this emerging dual-action approach.
Can TN-001 avoid hallucinogenic pitfalls while delivering rapid antidepressant effects?
Transneural’s TN-001 shows rapid neuroplasticity without hallucinogenic effects. Find out what this could mean for MDD and PTSD treatment strategies.